Key Financials

 

Consolidated Key Figures

(thousands of €, if not stated otherwise) 31/12/2017 31/12/2016 31/12/2015
INCOME STATEMENT
Revenues 127,087 129,519 39,563
Other income 28,830 22,093 21,017
R&D expenditure (218,502) (139,573) (129,714)
S, G&A expenses (27,218) (23,530) (20,308)
Operating expenses (245,720) (163,103) (150,023)
Operating loss (89,802) (11,491) (89,444)
Net financial results (25,705) 65,737 (30,184)
Taxes (198) (235) 1,218
Net income / loss (-) (115,704) 54,012 (118,410)
 
BALANCE SHEET
Cash, cash equivalents and restricted cash 1,152,369 980,909 348,216
R&D incentives receivables 75,783 64,342 58,545
Assets 1,286,274 1,083,338 442,514
Shareholders' equity 1,011,983 758,701 364,999
Deferred income 219,892 285,612 39,806
Other Liabilities 54,399 39,025 37,709
 
CASH FLOW
Operational cash burn (-) / operational cash flow (*) (154,089) 231,881 (121,145)
Cash flow from financing activities 353,357 395,996 271,370
Effect of currency exchange rate fluctuation on cash and cash equivalents (27,808) 4,816 118
Increase in cash, cash equivalents and restricted cash 171,460 632,693 150,343
Cash, cash equivalents and restricted cash on 31 December 1,152,369 980,909 348,216
 
FINANCIAL RATIOS
Number of shares issued on 31 December 50,936,778 46,256,078 39,076,342
Basic income / loss (-) per share (in €) (2.34) 1.18 (3.32)
Diluted income / loss (-) per share (in €) (2.34) 1.14 (3.32)
Share price on 31 December (in €) 78.98 60.94 56.76
Total group employees on 31 December (number) 600 508 435

Employees per site as of 31 December 2017

(*) The operational cash burn (or operational cash flow if this performance measure is positive) is equal to the sum of the net cash flows generated / used (-) in operating activities and the net cash flows generated / used (-) in investing activities minus (i) the proceeds or cash used, if any, in acquisitions or disposals of businesses; and (ii) the movement in restricted cash, if any. This alternative performance measure is in our view an important metric for a biotech company in the development stage. For 2016, the operational cash flow generated represented €231.9 million, which was significantly impacted by the upfront payment from Gilead of €275.6 million.